doi: 10.3389/fphar.2022.1026182
brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetryzoline, tramazoline, xylometazoline) and those stimulants included in the 2026 Monitoring Program* * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2026 Monitoring Program and are not considered Prohibited Substances
Key active ingredients include L-Glutathione (Free Form) (Reduced)
J Hazard Mater 388:122061
After repeated IM administration of BPC157 at 100 g/kg for seven consecutive days, the plasma concentration versus time curve (Figure 1C) and pharmacokinetic parameters (Table 3) were similar to those observed after a single IM injection at a dose of 100 g/kg, except for a slight increase in C max and AUC 0t